C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.

CCCC has been the subject of several recent research reports. TD Cowen restated a “buy” rating on shares of C4 Therapeutics in a report on Thursday, February 26th. Wall Street Zen upgraded shares of C4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. boosted their price objective on shares of C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Monday, April 20th. Finally, Barclays boosted their price objective on shares of C4 Therapeutics from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $3.85 on Friday. C4 Therapeutics has a one year low of $1.36 and a one year high of $4.60. The firm has a market cap of $425.69 million, a P/E ratio of -3.24 and a beta of 2.92. The firm has a 50-day simple moving average of $3.15 and a 200-day simple moving average of $2.63.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.05. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. The business had revenue of $6.15 million during the quarter, compared to analyst estimates of $4.42 million. On average, research analysts predict that C4 Therapeutics will post -0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. SummitTX Capital L.P. bought a new position in shares of C4 Therapeutics during the 1st quarter worth approximately $28,000. CTC Alternative Strategies Ltd. bought a new position in shares of C4 Therapeutics during the 1st quarter worth approximately $28,000. Zacks Investment Management bought a new position in shares of C4 Therapeutics during the 3rd quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd bought a new position in shares of C4 Therapeutics during the 3rd quarter worth approximately $43,000. Finally, Delta Investment Management LLC bought a new position in shares of C4 Therapeutics during the 4th quarter worth approximately $38,000. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.